The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study

Clinical Therapeutics

Volumn 28, Issue 7, 2006, Pages 1012-1021

  Sakamoto, Kenji ^a   Sakamoto, Tomohiro ^a   Ogawa, Hisao ^a  

^a KOJIROH) Investigators   (Japan)

Author keywords

adiponectin; coronary artery disease; high density lipoprotein cholesterol.; Pravastatin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; PRAVASTATIN; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASIAN; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; ECZEMA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; LIPID BLOOD LEVEL; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PILOT STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PILOT PROJECTS; POISSON DISTRIBUTION;

EID: 33748590264     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.07.001     Document Type: Article

References (33)

1. Maeda K., Okubo K., Shimomura I., et al. Analysis of an expression profile of genes in the human adipose tissue. Gene 190 (1997) 227-235
2. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 24 (2004) 29-33
3. Maeda K., Okubo K., Shimomura I., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 221 (1996) 285-289
4. Letter. Kojima S., Funahashi T., Sakamoto T., et al. The variation of plasma concentrations of a novel, adipocyte, derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89 (2003) 667
5. Maruyoshi H., Kojima S., Funahashi T., et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 91 (2004) 1026-1030
6. Maruyoshi H., Kojima S., Otsuka F., et al. Hypoadiponectinemia is associated with coronary artery spasm in men. Circ J. 69 (2005) 1154-1156
7. Kojima S., Funahashi T., Maruyoshi H., et al. Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma. Thromb Res. 115 (2005) 483-490
8. Opie L., and Gersh B. Drugs for the Heart. 6th ed. (2005), Elsevier Saunders, Philadelphia, Pa
9. Schwartz G., Olsson A., Ezekowitz M., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285 (2001) 1711-1718
10. Herd J., Ballantyne C., Farmer J., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 80 (1997) 278-286
11. Shepherd J., Cobbe S., Ford I., et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333 (1995) 1301-1307
12. Albert M., Danielson E., Rifai N., Ridker P., and PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP. Evaluation (PRINCE): A randomized trial and cohort study. JAMA 286 (2001) 64-70
13. Abe K., Nakayama M., Yoshimura M., et al. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: A relation with the -786>C polymorphism. Pharmacogenet Genomics 15 (2005) 329-336
14. Chu C., Lee K., Lee M., et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol. 97 (2006) 646-650
15. Koh K., Quon M., Han S., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol. 45 (2005) 1649-1653
16. Koh K., Quon M., Han S., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
17. Nakamura H. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. Program and abstracts of the American Heart Association Scientific Sessions. Dallas, Texas. Late Breaking Clinical Trials IV (November 13-16, 2005)
18. Takano T., Yamakawa T., Takahashi M., et al. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 13 (2006) 95-100
19. Yu Y., Ohmori K., Chen Y., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol. 44 (2004) 904-913
20. Guclu F., Ozmen B., Hekimsoy Z., and Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 58 (2004) 614-618
21. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 8 (2002) 1288-1295
22. Berg A., Combs T., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 7 (2001) 947-953
23. Yasue H., Horio Y., Nakamura N., et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: Possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 74 (1986) 955-963
24. Rifai N., Tracy R., and Ridker P. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 45 (1999) 2136-2141
25. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
26. Laufs U., La Fata V., Plutzky J., and Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
27. Rasmussen L., Hansen P., Nabipour M., et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J. 360 (2001) 363-370
28. Epub. Landsberger M., Wolff B., Jantzen F., et al. Cerivastatin reduces cytokine-induced surface expresion of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis (March 8, 2006)
29. Garlichs C., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
30. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
31. Wiesbauer F., Kaun C., Zorn G., et al. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: A comparative study using, different statins. Br J Pharmacol. 135 (2002) 284-292
32. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 19 (2005) 117-125
33. Szapary P., Bloedon L., Samaha F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 26 (2006) 182-188